StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.65−0.01 (-0.18%)

Close on Nov 16, 2026Market cap $490.25MP/E –Yield –

Valneva r&d expenses

Research and development expenses are spending on new products and technology.

Valneva's R&D Expenses for the twelve months ending Jun 30, 2026 was €83.10M, up 8.1% year over year. For fiscal 2025 it was €85.30M, up 15.1% from the year before. The highest annual figure on record is €173.28M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€85.30M+15.1%
FY2024Dec 31, 2024€74.14M+23.8%
FY2023Dec 31, 2023€59.89M-42.9%
FY2022Dec 31, 2022€104.92M-39.5%
FY2021Dec 31, 2021€173.28M+105.2%
FY2020Dec 31, 2020€84.45M+122.1%
FY2019Dec 31, 2019€38.02M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€15.02M-14.1%
Q1 FY2026Mar 31, 2026€15.22M+1.8%
Q4 FY2025Dec 31, 2025€25.57M-0.0%
Q3 FY2025Sep 30, 2025€27.29M+44.5%
Q2 FY2025Jun 30, 2025€17.49M+5.7%
Q1 FY2025Mar 31, 2025€14.95M+13.9%
Q4 FY2024Dec 31, 2024€25.58M+44.7%
Q3 FY2024Sep 30, 2024€18.88M+16.3%
Q2 FY2024Jun 30, 2024€16.55M+38.9%
Q1 FY2024Mar 31, 2024€13.13M-6.6%
Q4 FY2023Dec 31, 2023€17.67M-40.2%
Q3 FY2023Sep 30, 2023€16.24M-30.9%
Q2 FY2023Jun 30, 2023€11.91M-61.8%
Q1 FY2023Mar 31, 2023€14.07M-32.0%
Q4 FY2022Dec 31, 2022€29.54M-47.3%
Q3 FY2022Sep 30, 2022€23.50M-39.0%
Q2 FY2022Jun 30, 2022€31.19M-38.8%
Q1 FY2022Mar 31, 2022€20.69M-25.4%
Q4 FY2021Dec 31, 2021€56.05M–
Q3 FY2021Sep 30, 2021€38.50M–
Q2 FY2021Jun 30, 2021€51.01M–
Q1 FY2021Mar 31, 2021€27.73M–

More Valneva figures

See a number that looks wrong?